CClinicalTrials.gg
Sign In
CompletedNCT06620744DUETUpdated Jun 5, 2025

Magnetocardiography (MCG) Device Use in Patients With Elevated Troponin

An interventional study of Sponsor MCG deivce in ACS - Acute Coronary Syndrome, sponsored by SB Technology, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by SB Technology, Inc. · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 5 months ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This prospective device study will examine the feasibility of MCG data collection in a hospital setting using the SandboxAQ MCG device as a potential method to more accurately and quickly quantify cardiac disease of patients with elevated Troponin.

02

Conditions studied

  • ACS - Acute Coronary Syndrome

Keywords

  • magnetocardiography
  • MCG
03

In context

Acute Coronary Syndrome

1,461 studies on the registry are indexed under Acute Coronary Syndrome; 267 are open to participants now.

This study's enrollment of 40 is below the median of 200 across 869 interventional studies indexed under Acute Coronary Syndrome.

Browse Acute Coronary Syndrome studies →

Lead sponsor

SB Technology, Inc. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Received a positive hs-cTnI based on the institutions laboratory normal value ranges (e.g. female ≥14 and male ≥35)

Exclusion criteria

Exclusion Criteria:

  • Present STEMI
  • Having an active atrial fibrillation episode as seen on 12-lead ECG
  • Clear non-ischemic cause for symptoms (e.g. trauma)
  • Active thoracic metal implants
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Sponsor MCG Device

    All participants will receive a scan from the sponsor's MCG device.

    Device: Sponsor MCG deivce

Interventions

  • DeviceSponsor MCG deivce

    Unshielded device measuring cardiac magnetic fields.

06

What researchers measure

Primary outcomes

  1. Proportion (%) of all collected MCG data that meets the necessary data quality. requirements and are deemed suitable for analysis.

    MCG Data Quality

    Time frame: Per-scan, on average 5 minutes, day of enrollment

Secondary outcomes

  1. Sandbox MCG safety

    Device-related adverse events

    Time frame: 30-days

07

Study locations

1 site
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10019, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06620744
Lead sponsor
SB Technology, Inc.
Responsible party
Sponsor
First posted
Oct 1, 2024
Start date
Sep 21, 2024
Primary completion
Apr 15, 2025
Completion
Apr 15, 2025
Last update
Jun 5, 2025

Study contacts

Kit Yee Au-Yeung, PhD
study director · SB Technology, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Acute Coronary Syndrome→

Other studies from this sponsor

SB Technology, Inc.

Start the discussion